Scot Silber R.Ph.
Scot Silber R.Ph. graduated from the University of Wyoming School of Pharmacy in 1982. Following his graduation, he relocated to Las Vegas and commenced his pharmacy career as a hospital pharmacist. Driven by an entrepreneurial spirit, Scot purchased his first pharmacy in 1984, which eventually evolved into the largest specialty pharmacy and medical supply distribution company, shipping products to all 50 states.
In addition to his professional endeavors, Scot was one of the founders of the NEVADA Childhood Cancer Foundation and has dedicated 33 years of service as Chairman of the Board. Furthermore, he served in the US Army.
Core Strengths
- Pharmacy Regulation
- Compounding knowledge
- 40 years pharmacy experience
- Founder of the Nevada Childhood Cancer Foundation
- Extensive Pharmaceutical knowledge
“Pharmacists are consistently ranked among the top five most trustworthy and ethical professionals in the nation. We take pride in our commitment to education, expertise, and a dedication to transparency.” Scot Silber – NMeds | Managing Partner
What is GLP-1 semaglutide
GLP-1 semaglutide is a medication that acts as a glucagon-like peptide-1 (GLP-1) receptor agonist, mimicking the action of the natural GLP-1 hormone in the body. It is primarily used to manage type 2 diabetes and assist with weight loss. By enhancing insulin secretion, reducing glucagon release, and slowing gastric emptying, semaglutide helps regulate blood sugar levels and promotes significant weight loss. Additionally, it has been shown to reduce the risk of cardiovascular events such as heart attacks and strokes. Semaglutide is typically administered via a once-weekly subcutaneous injection, making it a convenient and effective option for patients. It is marketed under brand names like Ozempic for diabetes management and Wegovy for weight loss.
What are key benefits of GLP-1 Semaglutide
Semaglutide helps lower blood sugar levels in individuals with type 2 diabetes by stimulating insulin secretion and inhibiting glucagon release.
Semaglutide has been shown to promote significant weight loss, which is beneficial for individuals with obesity or those looking to manage their weight alongside diabetes.
Clinical studies have demonstrated that semaglutide can reduce the risk of major cardiovascular events, such as heart attack and stroke, in patients with type 2 diabetes.
Semaglutide is available in a once-weekly injection form, providing a convenient option for patients and improving adherence to treatment compared to daily medications.
Semaglutide helps decrease appetite and caloric intake, contributing to weight loss and better overall metabolic health.
By effectively managing blood sugar levels and promoting weight loss, semaglutide can enhance the overall quality of life for individuals with type 2 diabetes and obesity, reducing the burden of disease and associated complications.